uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
| Revenue (TTM) | $18.67M |
| Gross Profit (TTM) | $-114.71M |
| EBITDA | $-182.92M |
| Operating Margin | -872.00% |
| Return on Equity | -157.60% |
| Return on Assets | -15.70% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $4.67 |
| Price-to-Book | 9.15 |
| Price-to-Sales (TTM) | 80.91 |
| EV/Revenue | 118.82 |
| EV/EBITDA | 1.40 |
| Quarterly Earnings Growth (YoY) | -18.20% |
| Quarterly Revenue Growth (YoY) | 11.00% |
| Shares Outstanding | $69.37M |
| Float | $57.52M |
| % Insiders | 1.26% |
| % Institutions | 98.10% |
Volatility is currently expanding
uniQure (QURE) is rated a Speculative Buy with a $47 price target, implying 115% upside. QURE's Huntington's gene therapy BLA is under FDA accelerated review, with a decision expected around November 1. Three-year data met both FDA endpoints, showing 75% slowing of composite and 60% slowing of Total Functional Capacity.
New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
On Tuesday, Sep. 29, uniQure reported four-year AMT-130 data for Huntington's Disease that included cUHDRS & TFC four-year data. cUHDRS at year 4 showed 44% slowing, with a non-significant p=0.144. Per QURE, this may have been due to missing data & “survivor bias” in the external control arm. TFC (total functional capacity) data consistently show >60% slowing of disease progression with statistically significant p-values, albeit nominal ones. TFC is the FDA-aligned confirmatory p3 trial's primary endpoint.
uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside.
uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations.
uniQure NASDAQ: QURE reported updated Phase I/II data for its investigational Huntington's disease gene therapy, ifezuntirgene inilparvovec, or AMT-130, including 36-month results from all high-dose patients and 48-month results from the first 12 high-dose patients to reach that milestone.
uniQure N.V. shares plunged over 40% after 48-month AMT-130 data showed reduced disease progression benefits versus prior 36-month results. QURE's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review for accelerated approval despite recent volatility. Durability concerns arose as high-dose benefit dropped from 75% at 36 months to 44% at 48 months, though data attrition may have impacted control comparisons.
LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QURE and any ticker you trade — then tracks every position and per-strategy win rate.
